UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

CUSIP No. 37250B104

1.

Names of Reporting Persons.
Defiante Farmacêutica S.A.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

o

3.

SEC Use Only

4.

Citizenship or Place of Organization
Portugal

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
0

6.

Shared Voting Power
0

7.

Sole Dispositive Power
0

8.

Shared Dispositive Power
0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
0

10.

Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
0%

12.

Type of Reporting Person (See Instructions)
CO

Item 1(a).

Name of Issuer:
Gentium S.p.A.

Item 1(b).

Address of Issuer’s Principal Executive Offices:
Piazza XX Settembre 2, 22079, Villa Guardia (Como), Italy

Item 2(a).

Name of Person Filing:
This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

(i)            Defiante Farmacêutica S.A. (“Defiante”)

Item 2(b).

Address of Principal Business Office or, in none, Residence:
(i)            Defiante Farmacêutica S.A.

Rua dos Ferreiros, 260

Funchal-Madeira (Portugal) 9000-082

Item 2(c).

Citizenship:
(i)            Defiante is a Portuguese corporation.

Item 2(d).

Title of Class of Securities:
Ordinary Shares, par value €1.00 per share.  The Ordinary Shares are listed for trading on the NASDAQ Global Market in the form of American Depositary Shares.

Item 2(e).

CUSIP Number:
37250B104

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:

This Item 3 is not applicable

Item 4.

Ownership:

Defiante

(a)

Amount beneficially owned:   

0

(b)

Percent of class:   

0%

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:   

0

(ii)

Shared power to vote or to direct the vote:

0

(iii)

Sole power to dispose or to direct the disposition of:

0

(iv)

Shared power to dispose or to direct the disposition of:

0

Item 5.

Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following   x.

On December 5, 2013, Defiante merged with and into Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (“STIFR”) (the “Merger”).  Pursuant to the Merger, STIFR succeeded to all of the assets and liabilities of Defiante and became, by operation of law, the direct beneficial owner of the Issuer’s Common Stock beneficially owned by Defiante immediately prior to the Merger.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

This is an exit filing made by Defiante.  STIFR, as successor owner to Issuer’s Common Stock previously held by Defiante, has filed a separate Schedule 13G on the same day as this filing in order to report its beneficial ownership of more than 5% of the Common Stock of the Issuer.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not Applicable

Item 8.

Identification and Classification of Members of the Group:

Not Applicable

Item 9.

Notice of Dissolution of Group:

Not Applicable

Item 10.

Certification:

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

DEFIANTE FARMACÊUTICA S.A.

By:

/s/  Fabio Amabile

Name:  Fabio Amabile

Title:    Attorney-in-fact